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ABSTRACT Therapeutic drug monitoring for drug-resistant tuberculosis (TB) is likely to improve
treatment outcomes. While assessments of plasma drug levels can explain pharmacokinetic variability
among trial participants, these measures require phlebotomy and a cold chain, and are generally not
repeated frequently enough to characterise drug exposure over time. Using a novel multi-analyte assay, we
found evidence that higher anti-TB drug concentrations in hair, a non-biohazardous and noninvasively
collected biomatrix, predict extensively-drug resistant-TB clinical outcomes in a high-burden setting.
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Anti-tuberculosis drug concentrations in hair, a non-biohazardous and noninvasively collected
biomatrix, predict extensively drug-resistant-TB clinical outcomes in a high-burden setting.
http://ow.ly/80xi30o8qSa
Cite this article as: Metcalfe J, Bacchetti P, Gerona R, et al. Association of anti-tuberculosis drug
concentrations in hair and treatment outcomes in MDR- and XDR-TB. ERJ Open Res 2019; 5:
00046-2019 [https://doi.org/10.1183/23120541.00046-2019].
Copyright ©ERS 2019. This article is open access and distributed under the terms of the Creative Commons Attribution
Non-Commercial Licence 4.0.
This article has supplementary material available from openres.ersjournals.com
Received: Feb 28 2019 | Accepted: March 05 2019
https://doi.org/10.1183/23120541.00046-2019 ERJ Open Res 2019; 5: 00046-2019
ORIGINAL ARTICLE
TUBERCULOSIS
Introduction
In 2017, the World Health Organization estimated that 558000 individuals developed multidrug-resistant
tuberculosis (MDR-TB) [1]. Treatment outcomes remain poor, and result from clinical factors (HIV
co-infection, disease severity), poor adherence to complicated regimens, low anti-TB drug concentrations
from pharmacokinetic variability, suboptimal treatment regimens, or a combination of these. While
assessments of plasma drug levels can explain pharmacokinetic variability among trial participants, these
measures require phlebotomy and a cold chain, and are generally not repeated frequently enough to
characterise drug exposure over time in real-world programmes. Measuring drug levels in dried blood
spots circumvent some of these barriers, including the need for shipping samples via a cold chain, but
assays for many MDR-TB drugs in dried blood spots have not been developed. A noninvasive method that
does not require phlebotomy skills or biohazard precautions for long-term pharmacologic monitoring of
multiple simultaneous MDR-TB drugs, particularly in patients with HIV infection, is likely to significantly
advance the clinical management of MDR-TB.
Our group has extensive experience in the monitoring of antiretroviral concentrations in hair samples for
patients with HIV, and have found that antiretroviral hair levels display linear relationships with dose
within individuals [2], and are strong independent predictors of treatment outcomes [3]. In the field of TB,
subtherapeutic concentrations of drugs are common (in particular among patients with MDR-TB [4–6] and
those who are HIV co-infected [7–10]) and have been associated with acquired drug resistance [11–16],
adverse treatment outcomes in drug-sensitive TB [17–19], increased target size (i.e. number of unique
mutations conferring drug resistance) [20], and antagonistic (i.e. less than additive) drug interactions [21].
Furthermore, relative to antiretroviral combinations, TB regimens used for drug-resistant TB treatment are
more toxic, less standardised, and may pose even greater challenges for adequate patient adherence [22].
Methods
We hypothesised that anti-TB drug concentrations in hair are associated with clinical outcomes among
programmatically treated MDR-TB and extensively drug-resistant (XDR)-TB patients. Between July 1,
2016 and January 1, 2018, small, cosmetically unnoticeable hair samples (20–50 strands) were collected
from 47 patients, the majority of whom were undergoing programmatic, inpatient, directly observed
treatment for MDR- or XDR-TB at the Brooklyn Chest Hospital (Cape Town, South Africa). Of these, 46
(98%) were female, 31 (66%) were HIV-positive and 30 (64%) had XDR-TB (with the remainder having
MDR-TB). Patients were taking a median of five drugs (range 3–7), and the median amount of time on
drugs prior to hair sampling was 87 days (interquartile range (IQR) 50–160 days). No participants were
taking prothionamide, and only one participant (in a clinical trial) was taking pretomanid.
We analysed isoniazid (INH), ethambutol (EMB), pyrazinamide (PZA), levofloxacin (LFX), moxifloxacin
(MFX), linezolid (LZD), clofazimine (CFZ), bedaquiline (BDQ), pretomanid and/or prothionamide in a
multi-analyte panel using liquid chromatography/tandem mass spectrometry (LC-MS/MS) developed by
our group [23]. Measured drug concentrations in hair are summarised in table 1. We calculated a Z-score
for hair concentration of each drug (difference from the mean, divided by the standard deviation), and
then averaged these for all drugs for a given participant to obtain their mean anti-TB drug Z-score.
Because 3 cm of hair were assayed, representing ∼90 days of hair growth, concentrations of drugs not
TABLE 1 Observed anti-tuberculosis drug concentrations in small hair samples
Drug Patients n Median ng·mg-1 Quartile 1 Quartile 3
Isoniazid 22 1.67 0.30 2.47
Pyrazinamide 44 9.95 4.93 18.99
Ethambutol 34 1.15 0.69 2.01
Levofloxacin 28 35.16 23.76 59.99
Moxifloxacin 19 16.52 7.94 26.20
Bedaquiline 25 0.80 0.31 1.26
Clofazimine 31 0.82 0.51 1.45
Linezolid 22 11.22 3.89 41.71
Ethionamide 22 0.01 0.01 0.04
Pretomanid 1 1.14 1.14 1.14
Drug concentrations (in nanograms per milligram) are equal to those observed for individuals on the drug
for the entire hair growth window (i.e. 3 months); levels were scaled up for those not on the drug for this
duration. A refined adjustment was necessary for bedaquiline and clofazimine due to long half-life (refer
to main text).
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taken for the entire 90 days before collection were scaled up by a factor of 90/Days, where Days was the
number of days prior to collection that the drug was taken; only drugs that the patient was taking at the
time of hair collection for at least 14 days were considered. For BDQ and CFZ, a more elaborate
adjustment was used because of the long half-life of these drugs. From the first day of drug dosing, the
contribution of each dose taken to the systemic plasma concentration during each day in the hair growth
window was calculated, assuming rapid absorption of each dose followed by a half-life of 165 days for
BDQ and 70 days for CFZ, and these were summed over all 90 days to obtain a total number of dose-days
reflected in the hair sample (incorporation of drug into hair was assumed to be proportional to the
systemic plasma concentration.) The measured concentrations were then multiplied by 1000/(total
dose-days) to adjust for differing amounts of drug taken that should be reflected in the hair samples.
Kaplan–Meier methods calculated the time to our a priori primary composite outcome of time from start
of regimen to the first occurrence of treatment failure, relapse or death, and a Cox proportional hazards
model assessed the effect of mean drug Z-score on this outcome. The levels of each measured drug were
evaluated as individual predictors, restricted to those participants who were taking the drug at the time of
hair collection and continued taking it until the outcome or the end of follow-up. Because INH, PZA, and
CFZ concentrations were strongly right skewed, they were logarithmically transformed before Z-score
calculation. Because of potential greater efficacy in the setting of MDR-TB, a secondary predictor
combining only BDQ, LZD, MFX, LFX and CFZ (mean Z-score 5) was also assessed. A number of a priori
defined two-predictor models were evaluated. Treatment outcome categories conformed to the definitions
agreed for use by TB programmes for MDR-/XDR-TB, with the exception of loss to follow-up [24]. Loss
to follow-up was a priori excluded from our composite outcome because of the uncertain relationship
between sub-therapeutic drug exposure and treatment interruption, and the possibility that
supra-therapeutic drug levels (and toxicity) could more plausibly account for an opposing association.
Results
An overall Kaplan–Meier curve is shown in figure 1. Median follow-up time after hair sampling was 354 days
(IQR 43–482 days) among 23 individuals (out of the total sample size of 47) who were continuing treatment
(13 were treated as right-censored observations) or who had been lost to follow-up (10 were also censored) by
the end of the study. Median follow-up was 206 days (IQR 104–314 days) and 437 days (IQR 413–503 days)
among those with a composite poor outcome (11 failure events) and those who were considered
microbiologically cured (13 treated as never reaching the outcome), respectively. Univariate proportional
hazards regression found suggestive evidence that higher drug concentrations in hair may be substantially
associated with lower risk of poor treatment outcome (HR 0.60, 95% CI 0.27–1.34; p=0.21), although this had
wide uncertainty and did not reach statistical significance (table 2). Models that control for available
covariates are shown in the supplementary material. Controlling for concomitant HIV led to a slightly larger
effect size for hair concentration Z-score (HR 0.53), but others led to weaker effects (HR up to 0.71).
Discussion
We found preliminary evidence that anti-TB drug concentrations in hair, a novel and noninvasively
collected biomatrix, are associated with clinical outcomes for drug-resistant TB among programmatically
treated patients. Our panel assay, measuring 11 drugs used in second-line treatment regimens, was tested
in scalp hair for individuals on multiple regimens at varying time-points during treatment. Our data
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FIGURE 1 Time from hair sampling to composite outcome of treatment failure, relapse or death. Kaplan–
Meier curves shows time to treatment failure, relapse or death among patients treated for multidrug-
resistant or extensively drug-resistant-tuberculosis at Brooklyn Chest Hospital (Cape Town, South Africa).
Shaded area indicates the ±95% confidence interval for the survival function.
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suggest variability in hair concentrations for individual drugs likely due to individual pharmacokinetic
variability (given that drugs were directly administered by nurses during inpatient treatment), and an
effect size, despite not reaching statistical significance, suggesting a strong association between higher hair
levels and better clinical outcomes.
Our results have strong biologic plausibility in that low anti-TB drug exposure predisposes to prolonged
treatment, treatment failure, relapse and development of drug resistance [11, 25]. Although treatment in
our study was directly administered to hospitalised patients, inter-individual pharmacokinetic variability is
known to be influenced by body weight, sex, pharmacogenomics, comorbidities including HIV [26] and
diabetes mellitus [27], and even drug manufacturer [28]. Despite significant inter-individual variability in
drug exposure, as well clinical trials of TB therapeutics demonstrating the importance of
pharmacodynamics [29], therapeutic drug monitoring of anti-TB drugs is not routinely employed, mainly
due to feasibility issues. Hair collection is noninvasive and does not require phlebotomy skills, sterile
equipment, a cold chain or biohazard precautions during collection or shipping, features which enhance
feasibility in regions where resistant TB is prevalent.
A unique feature of hair levels relative to blood or urine concentrations is their ability to objectively assess
drug exposure over prior weeks to months rather than hours to days [30]. Hair grows remarkably
consistently in the occipital region of the scalp at approximately 1 cm per month, which allows hair to
serve as a marker of time. The ability to measure average exposure to drugs, rather than assessing a
snapshot of exposure via a shorter-term measure that may be influenced by intra-individual
pharmacokinetics or adherence variability, is a major strength of therapeutic drug monitoring using hair
levels. Moreover, hair can assess exposure over shorter periods of time than assessed in this paper (e.g.
1 month) and can be combined with plasma levels to provide information on patterns of drug exposure.
Limitations, however, include that hair cannot be collected from individuals with shaved heads or very
short hair, and that certain treatments, notably bleaching, can lower hair drug levels. Moreover, the assays
described here require sophisticated equipment (LC-MS/MS), limiting current feasibility to research
settings; however, lower cost assays using bench top systems are in development [31].
In conclusion, we provide promising evidence that noninvasive pharmacokinetic monitoring of small hair
samples at pre-specified intervals may detect low anti-TB drug exposure in resistant TB infection, which
could trigger interventions such as medication switches for drugs with very low levels or identifying
drug–drug interactions prior to treatment failure, thereby prolonging regimen durability. As with
conventional pharmacokinetic assessments, there is a need for randomised trials to assess the benefits of
real-time hair level monitoring in the management of drug-resistant TB.
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A. Esmail reports grants from NIH, during the conduct of the study. K. Dheda reports grants from NIH, during the
conduct of the study. M. Gandhi reports grants from NIH, during the conduct of the study.
TABLE 2 Proportional hazards models for association of hair drug concentrations and time to
failure
Predictor Patients n Events n HR (95% CI) p-value
Drug concentrations
Mean Z-score# 47 11 0.60 (0.27–1.34) 0.21
Isoniazid 22 3 1.40 (0.39–5.0) 0.61
Pyrazinamide 44 11 0.58 (0.31–1.09) 0.091
Ethambutol 34 6 0.79 (0.34–1.8) 0.58
Levofloxacin 28 5 1.21 (0.52–2.8) 0.66
Moxifloxacin 19 6 0.95 (0.42–2.2) 0.91
Bedaquiline 25 4 0.42 (0.10–1.7) 0.23
Clofazimine 31 8 0.54 (0.27–1.08) 0.081
Linezolid 22 3 0.55 (0.10–3.1) 0.50
Clinical and demographic risk factors
Age 47 11 0.61 (0.28–1.31) 0.20
HIV-positive 47 11 3.1 (0.67–14.4) 0.15
Mean anti-tuberculosis drug Z-score was calculated for each participant by averaging Z-scores (difference
from the mean, divided by the standard deviation) for all hair drug concentrations for a given participant;
this constituted the primary predictor. #: this was the primary predictor.
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